BN Business News
Add your company to Business Communicator →

Regulation & law · 29/11/2017

National Cancer Institute Considers Exclusive Patent License for Human Papillomavirus Vaccine

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to BravoVax Co., Ltd, a Chinese company, to manufacture and use patented technology for human papillomavirus vaccines.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights